<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00664534</url>
  </required_header>
  <id_info>
    <org_study_id>11806</org_study_id>
    <secondary_id>F3Z-EW-S020</secondary_id>
    <secondary_id>CTRI/2009/091/000609</secondary_id>
    <nct_id>NCT00664534</nct_id>
  </id_info>
  <brief_title>Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast</brief_title>
  <official_title>Comparison of Premixed Insulin Lispro Low-Mixture and Mid-Mixture Regimens With Separate Basal and Bolus Insulin Injections in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Oral Therapy Who Consume Light Breakfast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to look at how best to start and then gradually intensify (as needed)
      the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint</measure>
    <time_frame>48 weeks</time_frame>
    <description>Least Squares Mean (LSMean) values were adjusted based on a fixed effect linear regression model: HbA1c = Treatment + Country + HbA1c baseline value + Ramadan holiday between Visit 10 (Week 36) and Visit 12 (Week 48) (yes/no) in per-protocol (PP) population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Using Each Possible Final Insulin Regimen</measure>
    <time_frame>48 weeks</time_frame>
    <description>Insulin Regimens:
Lispro: Mid-Mix (MM) before noon; Low-Mix (LM) before evening (PM); MM before noon+LM before PM; LM before morning (AM)+MM before noon + LM before PM; MM before AM +MM before noon+LM before PM Glargine: Glargine once a day (QD); Glargine QD + 1 Lispro (noon or PM); Glargine QD + 2 Lispro (noon and PM); Glargine QD + 3 Lispro.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Over Time</measure>
    <time_frame>16 weeks, 32 weeks, and 48 weeks</time_frame>
    <description>Least Squares Mean (LSMean) values were adjusted based on a mixed effect linear regression model with a participant specific random effect: HbA1c = Treatment + Country + HbA1c baseline value + Ramadan holiday between Visit 10 (Week 36) and Visit 12 (Week 48) (yes/no) + visit + visit*treatment in Full Analysis Set (FAS) Population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving HbA1c Less Than or Equal to 6.5% and Less Than or Equal to 7% Over Time</measure>
    <time_frame>16 weeks, 32 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-point Self-monitored Blood Glucose Profiles</measure>
    <time_frame>16 weeks, 32 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Postprandial Blood Glucose Values</measure>
    <time_frame>Baseline, 16 weeks, 32 weeks and 48 weeks</time_frame>
    <description>Mean postprandial blood glucose values were assessed using GlycoMark, which is an FDA-approved blood test measuring levels of 1,5 anhydroglucitol (1,5 AG) in serum or plasma. When 1,5 AG values decrease, serum glucose levels increase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Daily Total, Basal and Prandial Insulin Dose</measure>
    <time_frame>16 weeks, 32 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline to Endpoint</measure>
    <time_frame>baseline, 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Percentage of participants with self-reported hypoglycemic episodes at any time during the study. A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has a blood glucose level of ≤70 mg/dL (3.9 mmol/L) (Roche plasma glucose) or ≤75 mg/dL (4.2 mmol/L) (IFCC Plasma Values), even if it was not associated with signs, symptoms, or treatment consistent with current guidelines (ADA 2005).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate Per 30 Days of All Self-reported Hypoglycemic Episodes</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>The hypoglycemia rate between two visits will be calculated as the total number of episodes between the two visits divided by the number of days between the visits, and then multiplied by 30 days (rate per patient per 30 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>A summary of serious adverse events (SAEs) and all other non-serious treatment-emergent adverse events (TEAE) is located in the Reported Adverse Event Module.
TEAEs are defined as events that are newly reported after randomization or reported to worsen in severity from baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premixed Insulin Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks</description>
    <arm_group_label>Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro Premix (mid-mixture and low-mixture)</intervention_name>
    <description>patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks</description>
    <arm_group_label>Premixed Insulin Lispro</arm_group_label>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Mellitus, Type 2

          -  have been receiving metformin plus at least one other oral antihyperglycemic
             medication (OAM) (sulfonylurea or Thiazolidinedione [TZD]) without insulin, for at
             least 90 days prior to Visit 1

          -  glycosylated hemoglobin (HbA1c) greater than or equal to 7.0% and less than 11.0%

          -  regularly consume a light breakfast (less than 15% of total daily calorie intake)

          -  capable and willing to follow the protocol

          -  give written consent

        Exclusion Criteria:

          -  are taking a TZD whose country label does not allow in combination with insulin

          -  are taking any glucose-lowering agents (other than specified in the inclusion criteria
             above)

          -  have a body mass index greater than 40 kg/m^2

          -  have a history of severe hypoglycemia in past 24 weeks

          -  are pregnant or may become pregnant

          -  women who are breastfeeding

          -  have significant cardiac disease

          -  have significant renal or liver disease

          -  undergoing therapy for a malignancy

          -  contraindications to study medications

          -  have an irregular sleep/wake cycle
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 am-5 pm Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <zip>K7A 4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bab El Louk</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heliopolis</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ahmedabad</city>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyderabaad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indore</city>
        <zip>452001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mumbai</city>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coatzacoalcos</city>
        <zip>96400</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aveiro</city>
        <zip>3814-501</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barreiro</city>
        <zip>2830</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lisbon</city>
        <zip>1250-203</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>020359</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Craiova</city>
        <zip>200000</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galati</city>
        <zip>6200</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>70057</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alicante</city>
        <zip>03114</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Badalona</city>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Cruz De Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ankara</city>
        <zip>06510</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Konya</city>
        <zip>42075</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Egypt</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Saudi Arabia</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2008</study_first_posted>
  <results_first_submitted>November 9, 2011</results_first_submitted>
  <results_first_submitted_qc>November 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 13, 2011</results_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glargine</title>
          <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
        </group>
        <group group_id="P2">
          <title>Premix Insulin Lispro</title>
          <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glargine</title>
          <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
        </group>
        <group group_id="B2">
          <title>Premix Insulin Lispro</title>
          <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="173"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="344"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.24" spread="8.621"/>
                    <measurement group_id="B2" value="54.33" spread="8.944"/>
                    <measurement group_id="B3" value="54.29" spread="8.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c)</title>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.07" spread="0.988"/>
                    <measurement group_id="B2" value="8.98" spread="0.945"/>
                    <measurement group_id="B3" value="9.02" spread="0.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint</title>
        <description>Least Squares Mean (LSMean) values were adjusted based on a fixed effect linear regression model: HbA1c = Treatment + Country + HbA1c baseline value + Ramadan holiday between Visit 10 (Week 36) and Visit 12 (Week 48) (yes/no) in per-protocol (PP) population.</description>
        <time_frame>48 weeks</time_frame>
        <population>PP Population=All participants who were randomized and met following criteria during study:
no violations of Inclusion/Exclusion Criteria
no early study discontinuation
compliant with treatment
received no other antihyperglycemic medication than allowed in Protocol, and have not been on systemic glucocorticoids for &gt;14 consecutive days.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Adjusted Glycosylated Hemoglobin (HbA1c) at Endpoint</title>
          <description>Least Squares Mean (LSMean) values were adjusted based on a fixed effect linear regression model: HbA1c = Treatment + Country + HbA1c baseline value + Ramadan holiday between Visit 10 (Week 36) and Visit 12 (Week 48) (yes/no) in per-protocol (PP) population.</description>
          <population>PP Population=All participants who were randomized and met following criteria during study:
no violations of Inclusion/Exclusion Criteria
no early study discontinuation
compliant with treatment
received no other antihyperglycemic medication than allowed in Protocol, and have not been on systemic glucocorticoids for &gt;14 consecutive days.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" lower_limit="7.27" upper_limit="7.82"/>
                    <measurement group_id="O2" value="7.40" lower_limit="7.15" upper_limit="7.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Noninferiority margin is defined as 0.4%. If the upper 95%CI for difference in LSMeans is below 0.4% then MIX arm will be declared noninferior to GLAR arm</non_inferiority_desc>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.42</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Least squares mean difference = (Premix insulin Lispro -Glargine)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Using Each Possible Final Insulin Regimen</title>
        <description>Insulin Regimens:
Lispro: Mid-Mix (MM) before noon; Low-Mix (LM) before evening (PM); MM before noon+LM before PM; LM before morning (AM)+MM before noon + LM before PM; MM before AM +MM before noon+LM before PM Glargine: Glargine once a day (QD); Glargine QD + 1 Lispro (noon or PM); Glargine QD + 2 Lispro (noon and PM); Glargine QD + 3 Lispro.</description>
        <time_frame>48 weeks</time_frame>
        <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had a measurement for the dependent variable at the time point, according to intent-to-treat (ITT) principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Using Each Possible Final Insulin Regimen</title>
          <description>Insulin Regimens:
Lispro: Mid-Mix (MM) before noon; Low-Mix (LM) before evening (PM); MM before noon+LM before PM; LM before morning (AM)+MM before noon + LM before PM; MM before AM +MM before noon+LM before PM Glargine: Glargine once a day (QD); Glargine QD + 1 Lispro (noon or PM); Glargine QD + 2 Lispro (noon and PM); Glargine QD + 3 Lispro.</description>
          <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had a measurement for the dependent variable at the time point, according to intent-to-treat (ITT) principles.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MM before noon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LM before PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MM before noon+LM before PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LM before AM+MM before noon+LM before PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MM before AM+MM before noon+LM before PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glargine QD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glargine QD+1 Lispro (noon or PM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glargine QD+2 Lispro (noon and PM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glargine QD+3 Lispro</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (not specified)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Over Time</title>
        <description>Least Squares Mean (LSMean) values were adjusted based on a mixed effect linear regression model with a participant specific random effect: HbA1c = Treatment + Country + HbA1c baseline value + Ramadan holiday between Visit 10 (Week 36) and Visit 12 (Week 48) (yes/no) + visit + visit*treatment in Full Analysis Set (FAS) Population.</description>
        <time_frame>16 weeks, 32 weeks, and 48 weeks</time_frame>
        <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Over Time</title>
          <description>Least Squares Mean (LSMean) values were adjusted based on a mixed effect linear regression model with a participant specific random effect: HbA1c = Treatment + Country + HbA1c baseline value + Ramadan holiday between Visit 10 (Week 36) and Visit 12 (Week 48) (yes/no) + visit + visit*treatment in Full Analysis Set (FAS) Population.</description>
          <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
          <units>percent glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>16 weeks (n=142,n=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" lower_limit="7.38" upper_limit="7.75"/>
                    <measurement group_id="O2" value="7.62" lower_limit="7.43" upper_limit="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 weeks (n=119, n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" lower_limit="7.22" upper_limit="7.63"/>
                    <measurement group_id="O2" value="7.46" lower_limit="7.26" upper_limit="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks (n=115,n=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.40" lower_limit="7.20" upper_limit="7.61"/>
                    <measurement group_id="O2" value="7.33" lower_limit="7.13" upper_limit="7.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
            <estimate_desc>Least squares mean difference = (Premix insulin Lispro - Glargine). 16 weeks</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean difference</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
            <estimate_desc>Least squares mean difference = (Premix insulin Lispro - Glargine). 32 weeks</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least squares mean difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
            <estimate_desc>Least squares mean difference = (Premix insulin Lispro - Glargine). 48 weeks</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving HbA1c Less Than or Equal to 6.5% and Less Than or Equal to 7% Over Time</title>
        <time_frame>16 weeks, 32 weeks and 48 weeks</time_frame>
        <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving HbA1c Less Than or Equal to 6.5% and Less Than or Equal to 7% Over Time</title>
          <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 HbA1c &lt;=7.0% (n=157, n=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 HbA1c &lt;=6.5% (n=157, n=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 HbA1c &lt;=7.0% (n=137, n=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1"/>
                    <measurement group_id="O2" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 HbA1c &lt;=6.5% (n=137, n=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 HbA1c &lt;=7.0% (n=130, n=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 HbA1c &lt;=6.5% (n=130, n=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2127</p_value>
            <p_value_desc>P-value is for Week 16 HbA1c &lt;=7.0%.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3281</p_value>
            <p_value_desc>P-value is for Week 16 HbA1c &lt;=6.5%</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2812</p_value>
            <p_value_desc>P-value is for Week 32 HbA1c &lt;=7.0%</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6963</p_value>
            <p_value_desc>P-value is for Week 32 HbA1c &lt;=6.5%</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0643</p_value>
            <p_value_desc>P-value is for Week 48 HbA1c &lt;=7.0%</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2524</p_value>
            <p_value_desc>P-value is for Week 48 HbA1c &lt;=6.5%</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-point Self-monitored Blood Glucose Profiles</title>
        <time_frame>16 weeks, 32 weeks and 48 weeks</time_frame>
        <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>7-point Self-monitored Blood Glucose Profiles</title>
          <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
          <units>millimoles per Liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 Before Breakfast (n=142, n=145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="0.17"/>
                    <measurement group_id="O2" value="7.36" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 Before Breakfast (n=126, n=130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.65" spread="0.14"/>
                    <measurement group_id="O2" value="7.20" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Before Breakfast (n=123, n=130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="0.15"/>
                    <measurement group_id="O2" value="6.94" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 After Breakfast (n=136, n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="0.25"/>
                    <measurement group_id="O2" value="9.92" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 After Breakfast (n=123, n=127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="0.24"/>
                    <measurement group_id="O2" value="9.16" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 After Breakfast (n=120, n=129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.88" spread="0.23"/>
                    <measurement group_id="O2" value="8.94" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Before Lunch (n=143, n=145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="0.21"/>
                    <measurement group_id="O2" value="7.66" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 Before Lunch (n=128, n=132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.00" spread="0.19"/>
                    <measurement group_id="O2" value="7.25" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Before Lunch (n=121, n=129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" spread="0.20"/>
                    <measurement group_id="O2" value="6.86" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 After Lunch (n=138, n=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.32" spread="0.25"/>
                    <measurement group_id="O2" value="9.37" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 After Lunch (n=127, n=130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.34" spread="0.23"/>
                    <measurement group_id="O2" value="8.69" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 After Lunch (n=120, n=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" spread="0.24"/>
                    <measurement group_id="O2" value="8.34" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Before Dinner (n=143, n=145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.84" spread="0.21"/>
                    <measurement group_id="O2" value="7.92" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 Before Dinner (n=129, n=132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.31" spread="0.19"/>
                    <measurement group_id="O2" value="7.39" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Before Dinner (n=120, n=129)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="0.21"/>
                    <measurement group_id="O2" value="7.19" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 After Dinner (n=140, n=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.68" spread="0.26"/>
                    <measurement group_id="O2" value="9.03" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 After Dinner (n=128, n=131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.64" spread="0.23"/>
                    <measurement group_id="O2" value="8.50" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 After Dinner (n=120, n=126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.87" spread="0.22"/>
                    <measurement group_id="O2" value="8.09" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 at 0300 Hours (n=114, n=120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.34" spread="0.33"/>
                    <measurement group_id="O2" value="7.22" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 at 0300 Hours (n=105, n=106)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="0.32"/>
                    <measurement group_id="O2" value="6.80" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 at 0300 Hours (n=104, n=107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="0.32"/>
                    <measurement group_id="O2" value="6.57" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Postprandial Blood Glucose Values</title>
        <description>Mean postprandial blood glucose values were assessed using GlycoMark, which is an FDA-approved blood test measuring levels of 1,5 anhydroglucitol (1,5 AG) in serum or plasma. When 1,5 AG values decrease, serum glucose levels increase.</description>
        <time_frame>Baseline, 16 weeks, 32 weeks and 48 weeks</time_frame>
        <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Postprandial Blood Glucose Values</title>
          <description>Mean postprandial blood glucose values were assessed using GlycoMark, which is an FDA-approved blood test measuring levels of 1,5 anhydroglucitol (1,5 AG) in serum or plasma. When 1,5 AG values decrease, serum glucose levels increase.</description>
          <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
          <units>microgram per milliliter (µg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=160, N=158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="5.804"/>
                    <measurement group_id="O2" value="5.69" spread="4.426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (N=143, N=141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.69" spread="6.161"/>
                    <measurement group_id="O2" value="9.52" spread="5.767"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (N=125, N=123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.54" spread="7.098"/>
                    <measurement group_id="O2" value="10.81" spread="6.824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (N=119, N=125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.90" spread="6.661"/>
                    <measurement group_id="O2" value="11.41" spread="7.344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6615</p_value>
            <p_value_desc>P-value for Baseline</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9798</p_value>
            <p_value_desc>P-value is for Week 16</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6169</p_value>
            <p_value_desc>P-value for Week 32</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7834</p_value>
            <p_value_desc>P-value for Week 48</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Daily Total, Basal and Prandial Insulin Dose</title>
        <time_frame>16 weeks, 32 weeks and 48 weeks</time_frame>
        <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Total, Basal and Prandial Insulin Dose</title>
          <population>Full Analysis Set: All participants who enrolled in this study, completed Screening, were randomized to one of the study treatments, and had at least one post baseline measurement for the dependent variable, according to intent-to-treat (ITT) principles.</population>
          <units>International Units per day (IU/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 Total Daily Insulin (N=156, N=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.94" spread="18.523"/>
                    <measurement group_id="O2" value="26.94" spread="15.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 Total Daily Insulin (N=135, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.80" spread="27.037"/>
                    <measurement group_id="O2" value="38.45" spread="23.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Total Daily Insulin (N=130, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.45" spread="31.402"/>
                    <measurement group_id="O2" value="46.20" spread="28.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Basal Insulin (N=156, N=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.53" spread="13.239"/>
                    <measurement group_id="O2" value="17.97" spread="10.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 Basal Insulin (N=135, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.05" spread="16.211"/>
                    <measurement group_id="O2" value="25.06" spread="15.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Basal Insulin (N=130, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.52" spread="17.194"/>
                    <measurement group_id="O2" value="30.12" spread="18.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 Prandial Insulin (N=156, N=155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="9.181"/>
                    <measurement group_id="O2" value="8.97" spread="5.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 Prandial Insulin (N=135, N=140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" spread="14.901"/>
                    <measurement group_id="O2" value="13.39" spread="8.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 Prandial Insulin (N=130, N=137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.94" spread="19.082"/>
                    <measurement group_id="O2" value="16.07" spread="10.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline to Endpoint</title>
        <time_frame>baseline, 48 weeks</time_frame>
        <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period and had measurement at baseline and endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline to Endpoint</title>
          <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period and had measurement at baseline and endpoint.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" lower_limit="2.09" upper_limit="3.31"/>
                    <measurement group_id="O2" value="2.61" lower_limit="2.01" upper_limit="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Premix Insulin Lispro minus Glargine.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Self-reported Hypoglycemic Episodes</title>
        <description>Percentage of participants with self-reported hypoglycemic episodes at any time during the study. A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has a blood glucose level of ≤70 mg/dL (3.9 mmol/L) (Roche plasma glucose) or ≤75 mg/dL (4.2 mmol/L) (IFCC Plasma Values), even if it was not associated with signs, symptoms, or treatment consistent with current guidelines (ADA 2005).</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period and had measurement at baseline and endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Self-reported Hypoglycemic Episodes</title>
          <description>Percentage of participants with self-reported hypoglycemic episodes at any time during the study. A hypoglycemic episode is defined as any time a participant feels that he/she is experiencing a sign or symptom that is associated with hypoglycemia, or has a blood glucose level of ≤70 mg/dL (3.9 mmol/L) (Roche plasma glucose) or ≤75 mg/dL (4.2 mmol/L) (IFCC Plasma Values), even if it was not associated with signs, symptoms, or treatment consistent with current guidelines (ADA 2005).</description>
          <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period and had measurement at baseline and endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1"/>
                    <measurement group_id="O2" value="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4935</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate Per 30 Days of All Self-reported Hypoglycemic Episodes</title>
        <description>The hypoglycemia rate between two visits will be calculated as the total number of episodes between the two visits divided by the number of days between the visits, and then multiplied by 30 days (rate per patient per 30 days).</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period and had measurement at baseline and endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Rate Per 30 Days of All Self-reported Hypoglycemic Episodes</title>
          <description>The hypoglycemia rate between two visits will be calculated as the total number of episodes between the two visits divided by the number of days between the visits, and then multiplied by 30 days (rate per patient per 30 days).</description>
          <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period and had measurement at baseline and endpoint.</population>
          <units>episodes per 30 days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.106"/>
                    <measurement group_id="O2" value="0.79" spread="1.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>A summary of serious adverse events (SAEs) and all other non-serious treatment-emergent adverse events (TEAE) is located in the Reported Adverse Event Module.
TEAEs are defined as events that are newly reported after randomization or reported to worsen in severity from baseline.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)</description>
          </group>
          <group group_id="O2">
            <title>Premix Insulin Lispro</title>
            <description>Premixed Insulin Lispro (mid-mixture or low-mixture)1,2 or 3 injections plus OAMs</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>A summary of serious adverse events (SAEs) and all other non-serious treatment-emergent adverse events (TEAE) is located in the Reported Adverse Event Module.
TEAEs are defined as events that are newly reported after randomization or reported to worsen in severity from baseline.</description>
          <population>Safety Set Population: All participants who received at least one dose of study drug during the treatment period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Premix Insulin Lispro</title>
          <description>Premixed Insulin Lispro (mid-mixture or low-mixture) 1, 2 or 3 injections plus OAMs</description>
        </group>
        <group group_id="E2">
          <title>Glargine</title>
          <description>Glargine +/- 1, 2 or 3 injections of insulin lispro plus OAMs</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Castleman's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="169"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="169"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="169"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="169"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="169"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="169"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="173"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="169"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="173"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

